Dissolution of metastatic thymic carcinoma–associated right atrial thrombus with rivaroxaban. (June 2020)

• Record Type: Journal Article
• Authors: Nimblette, Curlene; Seecheran, Rajeev; Kawall, Jessica; Seecheran, Valmiki; Persad, Sangeeta; Ramsaroop, Koomatie; Seecheran, Naveen Anand
• Is Part Of: SAGE open medical case reports. Volume 8(2020)
• Publication Date: 2020-06
• Subjects: Thymic carcinoma -- thymoma -- thrombus -- rivaroxaban -- direct oral anticoagulation; Clinical medicine -- Case studies -- Periodicals; 616.09
• DOI: 10.1177/2050313X20927596
• Languages: English
• ISSNs: 2050-313X

Abstract

Thymic carcinoma typically exhibits more clinically aggressive behavior and portends a worse prognosis as compared to thymoma. Venous thromboembolism is a significant cause of morbidity and mortality in oncologic patients. Traditionally, the standard-of-care management of cancer-associated venous thromboembolism has been therapeutic anticoagulation with low molecular weight heparins; however, with the advent of direct oral anticoagulants, there is an ongoing paradigm shift to transition to these novel agents in an attempt to attenuate cancer-associated venous thromboembolism events. We describe an exceedingly rare case of metastatic thymic carcinoma–associated right atrial thrombus with high-risk embolic features, which subsequently underwent near-complete dissolution with rivaroxaban after 3 months.